Ocugen, Inc. (OCGN)
| Market Cap | 279.22M |
| Revenue (ttm) | 7.26M |
| Net Income (ttm) | -44.90M |
| Shares Out | 287.86M |
| EPS (ttm) | -0.18 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 3,548,246 |
| Open | 0.940 |
| Previous Close | 0.950 |
| Day's Range | 0.921 - 0.994 |
| 52-Week Range | 0.345 - 2.105 |
| Beta | 3.71 |
| Analysts | Strong Buy |
| Price Target | 6.00 (+518.56%) |
| Earnings Date | Nov 7, 2024 |
About OCGN
Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve patients’ health. The company’s pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, currently under Phase 3 trials for the treatment of retinitis pigmentosa and Phase 1/2 trials for the treatment of leber congenital amaurosis; OCU410, a gene therapy un... [Read more]
Financial Performance
In 2023, Ocugen's revenue was $6.04 million, an increase of 142.60% compared to the previous year's $2.49 million. Losses were -$63.08 million, -27.33% less than in 2022.
Financial StatementsAnalyst Forecast
According to 2 analysts, the average rating for OCGN stock is "Strong Buy." The 12-month stock price forecast is $6.0, which is an increase of 518.56% from the latest price.
News
Ocugen to Present at the 2024 Cell & Gene Meeting on the Mesa
MALVERN, Pa., Oct. 02, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell...
Ocugen to Participate in a Fireside Chat at Chardan's 8th Annual Genetic Medicines Conference
MALVERN, Pa., Sept. 24, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cel...
Kaskela Law LLC Announces Shareholder Investigation of Ocugen, Inc. (NASDAQ: OCGN) and Encourages Investors to Contact the Firm
PHILADELPHIA--(BUSINESS WIRE)--Kaskela Law LLC announces that it is investigating Ocugen, Inc. (NASDAQ: OCGN) on behalf of the company's shareholders. Since July 2024, shares of Ocugen's stock have de...
Ocugen Extends Cash Runway As OCU400 Nears Key Milestones In Phase 3
Ocugen continues advancing its gene therapy pipeline, with OCU400 in Phase 3 trials for retinitis pigmentosa, targeting FDA approval by 2026. OCU400 has received the FDA's RMAT designation and is supp...
Ocugen Chairman, CEO & Co-founder, Dr. Shankar Musunuri, to Speak During U.S.-India Initiative on Critical and Emerging Technology Workshop
MALVERN, Pa., Sept. 09, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and...
Ocugen CSO to Participate in 5th Annual Gene Therapy for Ophthalmic Disorders Summit
MALVERN, Pa., Sept. 05, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cel...
Ocugen to Participate in a Fireside Chat at the H.C. Wainwright 26th Annual Global Investment Conference
MALVERN, Pa., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cel...
Ocugen Announces Completion of Dosing in Subjects with Stargardt Disease in High Dose Cohort of Phase 1/2 GARDian Clinical Trial of OCU410ST—A Modifier Gene Therapy
MALVERN, Pa., Aug. 28, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and ...
Ocugen, Inc. Announces Health Canada Approval to Initiate Phase 3 Clinical Trial for OCU400 – Modifier Gene Therapy for Broad Retinitis Pigmentosa Indication
MALVERN, Pa., Aug. 26, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and ...
Ocugen, Inc. Investor Alert (NASDAQ: OCGN): Schubert Jonckheer & Kolbe LLP Investigating Potential Claims Against the Company's Officers and Directors Following Earnings Restatement and Possible Insider Trading
SAN FRANCISCO , Aug. 20, 2024 /PRNewswire/ -- Schubert Jonckheer & Kolbe LLP advises Ocugen, Inc. investors that the firm is investigating potential legal claims relating to an earnings restatement an...
Ocugen Provides Business Update with Second Quarter 2024 Financial Results
Conference Call and Webcast Today at 8:30 a.m. ET Actively dosing patients in OCU400 Phase 3 liMeliGhT clinical trial OCU410 preliminary safety and efficacy data expected later this year Expanded acce...
Ocugen, Inc. Announces FDA Approval of Expanded Access Program for Patients with Retinitis Pigmentosa
MALVERN, Pa., Aug. 05, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and ...
Ocugen, Inc. Announces Closing of $35 Million Public Offering of Common Stock
MALVERN, Pa., Aug. 02, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Nasdaq: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines,...
Ocugen, Inc. Announces Pricing of $35 Million Public Offering of Common Stock
MALVERN, Pa., July 31, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Nasdaq: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines,...
Ocugen, Inc. Announces Proposed Public Offering of Common Stock
MALVERN, Pa., July 31, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Nasdaq: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines,...
Ocugen to Host Conference Call on Thursday, August 8 at 8:30 A.M. ET to Discuss Business Updates and Second Quarter 2024 Financial Results
MALVERN, Pa., July 29, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell...
Ocugen, Inc. Announces Completion of Dosing in Subjects with Geographic Atrophy Secondary to dAMD in High-Dose Cohort of Phase 1/2 ArMaDa Clinical Trial of OCU410—A Novel Modifier Gene Therapy
• Initiated Phase 2 clinical trial MALVERN, Pa., July 25, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, ...
Ocugen: Paradigm Shift Gene Therapy Facing Cash Flow Hurdles
Ocugen's most advanced product candidate, OCU400, has started Phase 3 clinical trials, aiming for regulatory approval in the U.S. and Europe by 2026. The gene therapy platform shows promise in treatin...
Ocugen Announces Data and Safety Monitoring Board Approves Enrollment in High Dose Cohort 3 in GARDian Study for Stargardt Disease
• Established Medium Dose as Safe and Tolerable Dose in Current OCU410ST Clinical Trial • DSMB Determination to Proceed with High Dose Cohort Dosing
Ocugen, Inc. Announces First Patient Dosed in Phase 3 liMeliGhT Clinical Trial for OCU400—First Gene Therapy in Phase 3 with a Broad Retinitis Pigmentosa Indication
MALVERN, Pa., June 20, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and ...
DEADLINE TODAY: The Schall Law Firm Encourages Investors in Ocugen, Inc. with Losses to Contact the Firm
LOS ANGELES--(BUSINESS WIRE)--DEADLINE TODAY: The Schall Law Firm Encourages Investors in Ocugen, Inc. with Losses to Contact the Firm.
The Schall Law Firm Encourages Investors With Losses in Ocugen, Inc. to Touch Base With the Firm Before the June 10th Deadline
LOS ANGELES, CA / ACCESSWIRE / June 9, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Ocugen, Inc. ("Ocugen" or "the Com...
Reminder for the June 10th Deadline: The Schall Law Firm Encourages Investors With Losses in Ocugen, Inc. to Reach Out
LOS ANGELES, CA / ACCESSWIRE / June 7, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Ocugen, Inc. ("Ocugen" or "the Com...
June 10th Deadline Reminder: The Schall Law Firm Invites Ocugen, Inc. Investors With Losses To Connect
LOS ANGELES, CA / ACCESSWIRE / June 6, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Ocugen, Inc. ("Ocugen" or "the Com...
SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Ocugen
NEW YORK , June 6, 2024 /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Ocugen, Inc. ("Ocugen" or the "Company") (NASDAQ: OCGN) ...